Professional groups and industry-wide collaborations are emerging to drive the growth of healthcare innovation. The development of high-quality, evidence-based products and services is now being supported by the Digital Medicine Society (DiMe) as well as the existing Digital Therapeutic Alliance (DTA).
The use of digital tools for better diagnosis and outcomes is rapidly progressing. The global digital health market is expected to reach $ 223.7 billion within five years based on increasing penetration of mobile devices, remote patient monitoring, and growing demand for advanced information systems. These products could represent a fundamental shift in healthcare services and actionable data generation according to experts.
Individuals and companies have come together to foster the field of digital medicine in order to safely promote innovation. The Digital Medicine Society (DiMe) recently announced its launch “serving individuals at the intersection of the global healthcare and technology communities.”
New technologies must be effective, reliable and high quality in order to be adopted by practitioners. The Food and Drug Administration (FDA) is charged with clearing products based on safety and efficacy data. The responsibility to establish evidence-based and patient-centered standards for digital products is being undertaken by DiMe and DTA. With appropriate standards, digital health has the potential to empower patients through increased access to high-quality care, better clinical results and economic outcomes. Without the groundswell of industry leadership, digital health technologies could become ineffective or even pose inadvertent safety risks if not properly validated and secured.
The DTA industry association and DiMe professional society were founded to develop industry foundations through product category definitions, standards of quality, safety, and evidence generation, in addition to frameworks for scalability and sustainability. Both organizations share a long term vision of helping patients and clinicians meaningfully use and benefit from these products and digital solutions. DiMe supports individual professionals, whereas DTA supports the industry at the organizational level. Together, these two groups represent the internal drive within a rapidly-evolving industry to ensure that high-quality, evidence-based products are delivered to end users.
The recently launched DiMe is the professional society for the digital medicine community. It was founded to drive scientific progress and broad acceptance of digital medicine to enhance public health. It has the vision of advancing digital medicine to optimize human health; and mission to serve professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices.
Founded in 2017, DTA is an international non-profit trade association of industry leaders and stakeholders with the vision of enabling expanded access to high quality, evidence-based digital therapeutics for patients, healthcare providers, and payers in order to improve clinical and health economic outcomes.
Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are reviewed and cleared by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use.
Digital medicines are software-driven connected technologies that align with evidence-based medicine practices. These include digital therapeutics, as well as digital measurement, diagnostic, and monitoring tools. Given the diversity of digital medicine products and the breadth of their application, it is important that they adhere to industry-adopted core principles and best practices. Therefore, the development of professional standards, publication of reproducible results, and collaborations with patients, providers, payers, and regulators are necessary to help promote the safe delivery and adoption of these novel class of digital tools.